EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Epstein-Barr virus-associated malignancies with specific T cells



Treatment of Epstein-Barr virus-associated malignancies with specific T cells



Advances in Cancer Research 84: 175-201



Latent Epstein-Barr virus (EBV) infection is associated with a heterogeneous group of malignancies, including Burkitt's lymphoma, Hodgkin's disease, nasopharyngeal carcinoma, and lymphoproliferative disease (LPD). The development of adoptive immunotherapies for these malignancies is being fueled by the successful generation of allogeneic donor derived EBV-specific cytotoxic T cells (CTL) for the prevention and treatment of EBV-LPD after hematopoietic stem cell transplantation. This approach is being extended to EBV-LPD after solid organ transplantation by use of autologous and haploidentical EBV-specific CTL. For other EBV-associated malignancies, there is only limited clinical experience with EBV-specific CTL. With few exceptions, only patients with recurrent Hodgkin's disease have been treated with autologous EBV-specific CTL, and although the results have been promising, they do not include cures. Lack of CTL efficacy may reflect either down-regulation of immunodominant EBV proteins, which are major CTL targets, or the presence of inhibitory cytokines. Further improvement of EBV-specific CTL therapy for Hodgkin's disease will require improved methods to activate and expand CTL specific for the latent EBV genes expressed in Hodgkin's disease and to genetically modify the expanded CTL to render them resistant to inhibitory cytokines. If effective, such strategies could be applied not only to other EBV-associated malignancies, but also to a broad range of human tumors with defined tumor antigens and similar immune evasion strategies.

(PDF 0-2 workdays service: $29.90)

Accession: 035980401

Download citation: RISBibTeXText

PMID: 11883527



Related references

Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells. Cancer Science 99(8): 1633-1642, 2008

Establishment of epstein barr virus nuclear antigen expressing cell lines by infection of epstein barr virus genome negative human lymphoma cells with different epstein barr virus strains. International Journal Of Cancer: 161-166, 1976

Epstein barr virus lymphoid cell interactions 2. the influence of epstein barr virus replication cycle on natural killing and antibody dependent cellular cyto toxicity against epstein barr virus infected cells. Clinical and Experimental Immunology 48(3): 589-601, 1982

Relationship between the amounts of epstein barr virus dna and epstein barr virus nuclear antigen per cell clonability and tumorigenicity in 2 epstein barr virus negative lymphoma lines and their epstein barr virus converted sublines. International Journal of Cancer 31(2): 163-170, 1983

Induction of epstein barr virus dna demethylation and of epstein barr virus specific transcription in daudi cells treated with 12 o tetradecanoylphorbol 13 acetate and n butyrate. Intervirology 22(4): 201-210, 1984

Heterogeneity of epstein barr virus part 4 induction of a specific antigen by epstein barr virus from 2 transformed marmoset cell lines in ramos cells. International Journal of Cancer 22(2): 160-165, 1978

Rescue of transforming epstein barr virus from epstein barr virus genome positive epithelial hybrid cells transfected with subgenomic fragments of epstein barr virus dna. Proceedings of the National Academy of Sciences of the United States of America 80(6): 1726-1729, 1983

Molecular size variation of epstein barr virus induced nuclear antigen is determined by the epstein barr viral genome studies on sublines of epstein barr virus negative lymphomas converted with different epstein barr virus substrains and on somatic hybrids. Intervirology 22(2): 85-96, 1984

The epstein barr virus carrying beta 2 micro globulin hla deficient burkitt lymphoma line daudi is sensitive to epstein barr virus specific killer thymus derived cells of mononucleosis patients. Cancer Letters 7(1): 15-20, 1979

Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Current Opinion in Oncology 13(5): 360-367, 2001

Relationship between epstein barr virus dna and the epstein barr virus determined nuclear antigen in burkitts lymphoma biopsies and other lympho proliferative malignancies. International Journal of Cancer 13(6): 764-772, 1974

Generation in vitro of hla restricted epstein barr virus specific cyto toxic human t cells by autologous lympho blastoid cell lines the roles of previous epstein barr virus infection and fetal calf serum. International Journal of Cancer 29(1): 41-48, 1982

Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: Implications for immunotherapy of Epstein-Barr virus-associated malignancies. European Journal of Immunology 29(8): 2579-2589, 1999

Specific allergen-induced Epstein-Barr nuclear antigen-positive B cells from patients with chronic-active Epstein-Barr virus infections. Journal of Allergy and Clinical Immunology 78(2): 315-320, 1986